Last reviewed · How we verify
GSK Biologicals' investigational vaccine GSK2340273A
At a glance
| Generic name | GSK Biologicals' investigational vaccine GSK2340273A |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy of H1N1 Vaccines in Children Aged 6 Months to Less Than 10 Years of Age (PHASE3)
- Safety and Immune Response of Candidate H1N1 Influenza Vaccine GSK2340274A Following Seasonal Influenza Vaccination in Adults (PHASE1)
- Study of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Children Aged 10 to Less Than 18 Years (PHASE2)
- Immunogenicity and Safety of Pandemic Influenza Vaccines in Adults Aged 18 - 49 Years Old (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: